Update shared on 28 Oct 2025
Narrative Update on Siemens Healthineers
The consensus analyst price target for Siemens Healthineers was recently lowered by EUR 1 to EUR 61. Analysts are incorporating minor adjustments to growth and profitability expectations in their updated outlook.
Analyst Commentary
Analyst opinions on Siemens Healthineers highlight both encouraging prospects and areas of caution as they update forecasts and price targets.
Bullish Takeaways
- Bullish analysts maintain a positive outlook on the stock, keeping Buy ratings despite a slight adjustment in price targets.
- They continue to see value in Siemens Healthineers' long-term growth trajectory, supported by steady demand in healthcare technologies.
- Expectations are for the company to execute well on key projects that could drive incremental profitability in the future.
Bearish Takeaways
- Bearish analysts are cautious about near-term growth, which has led to a minor reduction in consensus price targets.
- They point to ongoing challenges related to macroeconomic factors that could slow revenue acceleration or margin expansion in the short term.
- There is some concern about the company's ability to sustain profitability improvements in light of shifting sector dynamics and increased competition.
What's in the News
- Aiforia Technologies has entered into a local agreement with Siemens Healthineers Finland to jointly co-market and sell AI-powered pathology solutions. This collaboration supports digital transformation and precision diagnostics in Finnish healthcare. (Key Developments)
- The Atellica DT 250 Analyzer was launched, enabling quality drug testing with faster results and broad capabilities for clinical and non-clinical settings. The analyzer can process up to 225 test results per hour. (Key Developments)
- Siemens Healthineers and Evident formed a strategic alliance to deliver a digital pathology workflow at Klinikum der Stadt Ludwigshafen am Rhein in Germany. This partnership aims to support improved patient care and diagnostics. (Key Developments)
- A new strategic agreement with Carna Health aims to expand AI-enabled chronic kidney disease screening, including point-of-care diagnostic systems for underserved global populations. (Key Developments)
- Siemens Healthineers raised its earnings guidance for 2025 and expects revenue growth of 5.5% to 6% due to stronger-than-anticipated performance and increased certainty from tariffs. (Key Developments)
Valuation Changes
- Discount Rate has risen slightly from 5.82% to 5.88%.
- Revenue Growth expectation has remained steady at 5.41%.
- Net Profit Margin estimate has remained steady at 11.58%.
- Future P/E ratio has edged up from 25.22x to 25.27x.
- Fair Value remains unchanged at €58.81.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.